Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with ...

Prior biliary tract surgery was previously considered a contraindication for laparoscopic biliary tract reoperation. However, it is now widely performed in patients with or without prior operations ...

Academic-center care was independently associated with higher complete oncologic resection rates and improved overall survival versus nonacademic facilities after adjustment for age, comorbidity, and ...

Overall mortality was low (n = 7), and the frequency of various complications varied by the type of procedure used to clear stones from the biliary tract. With respect to avoiding postoperative ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Data from the SWOG 1815 trial presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium showed that adding nab-paclitaxel (Abraxane) to gemcitabine (Gemzar) and ...

Gallbladder cancer and cholangiocarcinoma are different types of biliary tract cancer. They affect the same system in the body and cause similar symptoms, but they may require different treatments.

Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nab-paclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC). This is an ASCO ...

Medically reviewed by Robert Burakoff, MD Key Takeaways Most people do not experience any long-term effects of gallbladder ...